Author: Mark Du Bois

Ziccum CEO Ann Gidner was invited to the Swedish Ministry for Foreign Affairs for a roundtable discussion on the important topic of “Leveraging Technology and Innovation to Ensure Every Child is Vaccinated”. The gathering included the State secretary Diana Janse, Dr Sania Nishtar, CEO of Gavi Vaccine Alliance, Dr Anh Wartel, Regional Director of IVI, several national Ambassadors plus top level Swedish industry representatives and was moderated by Dr Karin Tegmark Wisell, the Swedish Ambassador of Global health.

Preventive healthcare is of utmost importance, to make scarce resources last for the entire human population. A key tool here is vaccination, preventing life-threatening diseases. Vaccines save lives and enables children a good start in life, laying the ground for a good public and global health. The CEO for Gavi, The Vaccine Alliance, Dr Sania Nishtar spoke about how innovative solutions such as drones being used to reach unvaccinated children in Nigeria. State Secretary Diana Janse expressed the appreciation from the Swedish Government for the results being achieved. As one of Gavi’s six original donors and a long standing partner, Sweden has demonstrated its commitment to ensure equitable access to vaccines and to improve health outcomes for the world’s most vulnerable populations. Thanks to these efforts, vaccines are now reaching children in remote areas who were previously excluded from the health care systems.

During the roundtable, Swedish companies with experiences in pioneering innovations in technology and sustainability discussed how they can contribute to reaching the 14.5 million children in the world who still lack vaccines, of which 11 million live in Gavi-partner countries. Ann Gidner gave an address on the importance of considering further technology innovation to truly enable equitable and sustainable vaccination. Applying Ziccum technology for robust and thermostable vaccine forms could offer a technology leap, overcoming a number of practical and economical hurdles with one solution.

LaminarPace and its potential for the vaccine industry got great interest from industry partners and institutions. The International Vaccine Institute is already planning to visit Ziccum in its facility for further discussion.

We are happy to share Omni’s article in Swedish highlighting Ziccum’s LaminarPace® technology. The article focuses on the remarkable potential of LaminarPace®, which enables the drying of fragile mRNA drugs and vaccines while eliminating the need for cold chain storage and transportation, leading to significant cost reductions.

Please follow the links to read the full article (in Swedish) either in Omni or OmniEkonomi:

https://omni.se/genomfor-nyemission-mojliggor-effektiva-biologiska-behandlingar/a/eMeElO

https://omniekonomi.se/genomfor-nyemission-mojliggor-effektiva-biologiska-behandlingar/a/63y458

Ziccum CEO Ann Gidner gave a compelling presentation at Stora Aktiedagarna, Stockholm on 27^th of November showcasing Ziccum’s groundbreaking LaminarPace technology, which transforms fragile liquid biologics into robust, thermostable dry powders while preserving drug activity and significantly reducing costs. This innovation is paving the way for a new era in the biopharmaceutical industry by eliminating the need for cold chain and enabling new drug delivery forms possible.

Don’t miss the chance to watch the presentation (in Swedish): https://youtu.be/B3iFEhtsAkE

We are pleased to share Aktiespararna’s article highlighting Ziccum’s LaminarPace® technology. The article focuses on Ziccum’s great potential when it comes to helping biopharmaceuticals to realization and the mRNA revolution, informative background of the company, current business model and promising market outlook, and information about its recently announced rights issue.

Please follow the link to read the full article (in Swedish) here: En teknologiplattform helt rätt i tiden | Aktiespararna

On November 21^st in Lund, Ziccum CEO Ann Gidner delivered an engaging presentation at BioStock Life Science Summit, highlighting the innovative LaminarPace technology, which garnered significant interest from investors and life science experts.

Please watch the full presentation here to learn more about LaminarPace, how it creates significant value in the biopharmaceuticals industry, its expansive market potential and the company’s business model plus on-going rights issue. https://youtu.be/RZ13iikjU5c

Ziccum CEO Ann Gidner was pleased to join The Future of Healthcare – Going Global with Citi on November 14th in Copenhagen. This exclusive, invite-only event serves as a gathering for senior executives from life sciences, biotechnology, and healthcare companies to explore the key trends shaping investor perspectives, recent shifts in the global capital-raising landscape, and strategies for expanding businesses.

CEO Ann Gidner: “It was great to be part of this interesting seminar and exchange ideas with industry CEOs and investors regarding new trends, dynamics and the industry outlook. Thank you for insightful presentations and great discussions. I was happy to get keen interest in our LaminarPace technology from industry executives.”

Ziccum gathered for an insightful and productive Inhalation Workshop on November 12^th. The meeting was focused on LaminarPace’s unique features particularly well suited for inhaled biopharmaceuticals. Strong, new data has confirmed that the unique particle engineering by LaminarPace® can make even inhaled mRNA/LNP possible. Other topics covered included the formulation aspects of inhaled powder for biologics, mucosal drug delivery, and the market outlook for inhaled biologics.

The workshop was attended by both the management team and board members of Ziccum, on-site and on-line, considering the importance of this focus area. Thank you everyone, looking forward to the next one!

Ziccum CEO Ann Gidner, along with Business Manager Ilkim Atmaca, participated in Bio-Europe, held in Stockholm, Sweden from November 4–6, 2024. As Europe’s leading life science partnering event, Bio-Europe provided an excellent platform for connecting with partners and top executives in the industry. Ziccum had an intense schedule filled with productive partnership meetings.

CEO Ann Gidner: “It was fantastic to reconnect with industry contacts and participate in exciting new collaboration meetings. Over these three days, we established a number of new business connections, and I’m very pleased with the positive feedback and new partnerships we formed. Thank you to everyone who made it a success—looking forward to taking this forward!”

To explore more about Ziccum’s LaminarPace technology and learn how it cuts costs, enables new treatments and allows for particle engineering perfectly suitable for inhalation, please attend Ziccum’s presentation at the Biostock Life Science Summit on November 21^st, 2024, at 13:15 covering the topic: “Unlocking the Biopharma Revolution: New Drug Delivery & Solved Drug Stability”

Please connect with Ziccum CEO Ann Gidner at the event to explore the key benefits of this groundbreaking technology, which formulates and dries even the most fragile biotherapeutics, transforming them into robust, thermostable dry powder forms. Don’t miss this opportunity to learn how LaminarPace is unlocking new possibilities for advanced drug delivery systems.

Book a meeting here: https://ziccum.com/about-us/contact/